The 3 analysts offering 12-month price forecasts for Plus Therapeutics Inc have a median target of 3.50, with a high estimate of 5.00 and a low estimate of 2.00. The median estimate represents a +588.03% increase from the last price of 0.51.
The current consensus among 3 polled investment analysts is to Buy stock in Plus Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.22
Reporting Date Nov 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.